NC318

DRUG2 trials

Sponsors

NextCure, Inc.

Conditions

Advanced or Metastatic Solid TumorsBreast CancerCRCCholangiocarcinomaEndometrial CancerHead and Neck Squamous Cell CarcinomaLung CancerMelanoma

Phase 1

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

CompletedNCT03665285

NextCure, Inc.Advanced or Metastatic Solid Tumors, Breast Cancer, Cholangiocarcinoma +6

Start: 2018-10-01End: 2023-04-11Updated: 2024-03-08

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

WithdrawnNCT04430933

NextCure, Inc.Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer

Start: 2021-12-06End: 2022-10-30Updated: 2021-08-18

Related Papers

EXTH-22. TARGETING A NEWLY DISCOVERED IMMUNE CHECKPOINT, SIGLEC-15, INCREASES ONCOLYTIC EFFICACY OF ZIKA VIRUS (ZIKV) IN GLIOBLASTOMA (GBM)

Neuro-Oncology2022-11-01

490 Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-0112 citations

Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.

Journal of Clinical Oncology2020-05-2011 citations